Pulmonx Corp (STU:4NI)
€ 6.95 0.15 (2.21%) Market Cap: 278.26 Mil Enterprise Value: 229.75 Mil PE Ratio: 0 PB Ratio: 3.17 GF Score: 63/100

Pulmonx Corp at Bank of America Healthcare Conference Transcript

May 10, 2022 / 07:40PM GMT
Release Date Price: €15.8 (-12.22%)
Travis Lee Steed
BofA Securities, Research Division - MD

Travis Steed, Medical Device Analyst at Bank of America, and we welcome Pulmonx up next. We have Glen French, CEO; and Derrick Sung, CFO. So thanks for being here. We'll hop into a fireside chat.

Questions & Answers

Travis Lee Steed
BofA Securities, Research Division - MD

So I guess, I just wanted to look at Q1, you just reported Q1 results and probably one of the more COVID-impacted smaller Med Tech companies, small cap companies in the space. So I just wanted to make sure, like we kind of level set where things were in Q1, the recovery in March and April into May, and so now that you have a little bit more visibility into the early part of the second quarter.

Glendon E. French
Pulmonx Corporation - CEO, President & Director

Right. Yes. So just as by way of background, we're significantly impacted by COVID because -- particularly when COVID consumes ICU beds. And Omicron was -- came on very quick and it hit basically all of our major market.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot